Clinical Trial Update: SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis [Phase 1]

View source ↗

Summary

This update notes a completed Phase 1 trial evaluating the metabolic effects of SGLT2 inhibitors in combination with metformin for non-alcoholic fatty liver dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• SGLT2 inhibitors (class)
• metformin (metformin)

Snippet

Sponsor: University of Oxford | Conditions: Non-alcoholic Fatty Liver Disease | Phase 1 | Status: COMPLETED